(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 December 2018 (27.12.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/234370 A1

(51) International Patent Classification:
C12N 5/078 (2010.01)

(21) International Application Number:
PCT/EP2018/066387

(22) International Filing Date:
20 June 2018 (20.06.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17305757.1 20 June 2017 (20.06.2017) EP

(71) Applicants: **INSTITUT CURIE** [FR/FR]; 26 rue d'Ulm, 75005 PARIS (FR). **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101, rue de Tolbiac, PARIS, 75013 (FR). **CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS -** [FR/FR]; 3, rue Michel Ange, PARIS, 75016 (FR).

(72) Inventors: **AMIGORENA, Sebastian**; 32 rue des Cordeliers, 75013 PARIS (FR). **PIAGGIO, Eliane**; 77 rue de la Mare, 75020 PARIS (FR). **GOUDOT, Christel**; 18 avenue Yves Cariou, 93150 LE BLANC MESNIL (FR). **PACE, Luigia**; Italian Institute for Genomic Medecine (IIGM) Via Nizza 52, 10100 Turin (IT). **ALMOUZNI, Geneviève**; 30 rue de l'Eglise, 92200 Neuilly sur Seine (FR).

(74) Agent: **CABINET PLASSERAUD**; 66 rue de la Chaussée d'Antin, 75440 PARIS CEDEX 09 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

WO 2018/234370 A1

(54) Title: IMMUNE CELLS DEFECTIVE FOR SUV39H1

(57) Abstract: The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.